Viatris, which Pfizer created in 2020, voluntarily withdrew extended-release products made at a plant in Ireland after an ...
In a randomized trial, both 100-mg and 300-mg monthly maintenance doses of extended-release buprenorphine improved opioid abstinence in patients with high-risk opioid use, with no new safety signals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results